The group's principal activities are to provide research and development in the biomedical industry, with an emphasis on anti-infective drugs. The group has completed various stages of planning and developing products containing its proprietary drugs viraplex(R) and mtch-24(TM). Both of these compounds show positive test results for treatment of a variety of enveloped viruses. An enveloped virus is one in which the infectious particle is surrounded by a coating made of protein, fatty substances and carbohydrate. Mtch-24(TM) which is effective against other enveloped viruses such as influenza, epstein-barr virus, respiratory syncytial virus (a virus which affects the respiratory system), pseudorabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus. Viraplex(R) is administered orally in capsule form as a prescription treatment for orofacial and genital herpes simplex virus infections in humans.
